Loading

International Journal of Clinical Anesthesiology

Local Anesthetic Systemic Toxicity (LAST): Mini Review

Review Article | Open Access
Article DOI :

  • 1. Department of Anesthesiology and Intensive Care Unit, Baskent University, Turkey
+ Show More - Show Less
Corresponding Authors
Nedim Çekmen, Department of Anesthesiology and Intensive Care Unit, Baskent University, Baskent University, Faculty of Medicine, Fevzi Cakmak Caddesi 10, Sokak No:45 Bahcelievler, 06490 Ankara, Turkey, Tel: 0312203 68 68-4867
INTRODUCTION

Local anesthetic systemic toxicity (LAST) is uncommon but has a significantly lethal adverse effect. LAST can be recognized, prevented, managed, and treated with awareness and thorough knowledge [1,2]. Due to recent advances in RA and popular techniques, large volume increases the potential risk of LAST using LAs inside and outside the operating room [1-3]. With the widespread use of LAs techniques, the incidence of peripheral nerve blocks is estimated to be between 0.03% and 0.27%. Many conditions contribute to the risk of developing LAST, such as the widespread use of high-volume facial plane interventions [1,3], the increased use of continuous catheter techniques [4], the use of multiple LAs techniques in the same patient [5], and tumescent anesthesia [6]. While increasing the success of RA techniques with its use, the US also increases the LAs dose and reduces the risk of anesthetic toxicity and complications [1-4]. LAs in daily practice, especially by anesthesiologists, surgeons, perioperative nurses, and medical personnel, have become widespread among emergency room doctors and dentists. In preventing and treating LAST, knowing the underlying mechanisms, risk factors, pharmacokinetics, and pharmacodynamics of LAs drugs are vital in clinical practice for the practicing physician. Anesthesiologists can lead the education and development of those who practice LAs in the hospital setting in preventing and managing LAST and improving patient safety [1,2,7]. This review emphasizes LAST’s importance in our anesthesia practice.

Local Anesthet?cs

LAs are divided into two groups according to their chemical structure. The groups are also aromatic. Quaternary amine (secondary or tertiary amine) with a lipophilic part (benzene ring) determines the intermediate bond between the hydrophilic part in its structure. If this bond is amino-ester, the ester (-COO-) group, amino amide, forms the amide (-NHCO-) group [8,9].

LAs are weak bases in solution present in charged and uncharged forms. When the amine nitrogen is protonated (quaternary), the lipid solubility of LAs gradually decreases. The protonated, charged form has a greater affinity for Na+ channels because it is more soluble and bound in water. The intermediate amine form is uncharged, more soluble in fat, and easily crosses the nerve membrane [8,9].

Pharmacodynam?cs

The differences in LAs are due to inert properties such as pKa, lipophilicity, and protein binding.

  • Lipophilicity: The potency of LAs
  • pKa: The onset of action of LAs
  • Protein binding: The duration of LAs

Pharmacok?net?cs

The systemic absorption rate of LAs determines the plasma concentration of LAs and the time it takes to reach these peak levels [8]. At the same time, serum concentration, injection site, and LAs dose are critical. Injection of the same amount of LAs depending on the vascular structure of the region, the highest blood peak concentrations in the water occur in order; Topical (mucosa)>intercostal block>epidural block>intrapleural block> plexus block>skin infiltration [8,9]. Ester-based LAs; are hydrolyzed by plasma esterases. They are stable and allergic to this group because their para amino benzoic acid breakdown products and reactions are more common. Amide-type LAs; in the liver metabolism by hepatic microsomal cytochrome P450 (CYP/CYP450) enzymes. Enzymes destroy them, are more stable, and allergic reactions are rarely observed in this group. Because of these differences, more amide-type LAs are used in the clinic [9].

The high serum concentration of LAs is due to systemic absorption or accidental intravascular injection. Both minor and significant may develop in LAST due to elevated serum concentration. Minor symptoms of LAST include numbness around the mouth and tongue, metallic taste, and visual and cognitive changes; Major symptoms are usually seizures, arrhythmias, and respiratory and cardiac arrest. LAST can be seen in the standard and very high doses without side effects [1,2,10]. Nevertheless, it is necessary to achieve the desired effect. The total amount of LAs should be the lowest [10].

Mechan?sm

LAs act in the interior of the voltage-gated sodium (VGNa+ ) channel. The VGNa+ channel consists of alpha and beta subunits. For LAs, the Alpha subunit functions as the functional ion channel, and the beta subunits modulate the kinetics and voltage dependence for activation/inactivation. LAs inhibit conduction in neuronal tissues by reversibly inhibiting ion transfer and neuronal depolarization [8-10]. LAs can interfere with cell membrane signaling, affecting multiple cellular cAMP processes and protein kinases [8,9]. LAs can also block Ca++, K+ , Na+ -K+ ATPase channels and other channels nAch (nicotinic acetylcholine, and NMDA (N-methyl-D-aspartate). The LAs also impair mitochondrial metabolism and disturb oxidative phosphorylation, ATP production, and ryanodine receptor at the sarcoplasmic reticulum (Figure 1) [8,10]. LAs reduce or stop potential action conduction by blocking Na+ channels in nerves. As a result, it first increases excitability in the CNS, leading to widespread depression. On the other hand, it reduces excitability in the heart and prolongs the refractory period. In addition, vasodilation occurs when vascular smooth muscle is affected and can lead to critical hemodynamic changes. LAST’s mechanisms and symptoms, as shown in Figure 1 [1,2,8-10]. LAST has a complex clinical picture because of the many sites affected by the LAs. A comparison of LAs according to potencies, duration of action, and maximum doses is given in Table 1 [8-10].

Presentat?on

LAST, in both SSS and CVS, occurs with findings that can be seen first in the stimulation period and then in the depression period, and this is presented in Table 2 [1,2]. The CNS is more sensitive than CVS for the risk of developing LAST. This means the serum concentration of LAs required to establish the clinical picture of LAST is lower in the CNS than in CVS. The most common LAST-related toxicity is CNS toxicity, with an incidence of 68-77% and often presenting first, whereas CVS toxicity is less frequent, although 40% occurs atypically [1,2,11,12].

R?sk Factors

LAST-related risk factors are patient, anesthetic, and practice setting factors. And these factors are presented in Table 3 [12].

Prevent?on

The basic principle in medicine is “Prevention is better than cure.” it should be treated accordingly. The main aim should be prevention, and RA applications should avoid LAST. It is essential to recognize LAST early, prevent it, and take the necessary safety measures to minimize its severity, reduce the risk factors, and monitor closely [12].

Dose Management

The first step in preventing LAST is administering the LAs dose individually according to the specified algorithms and clinical situation. Gradual bolus injections, slow injection over time, and light aspiration at intervals are recommended practices to avoid adverse effects. Making fractionated injections of LAs in fractional <5 mL is recommended, stopping for 30-45 seconds between injections [8-10]. Adding epinephrine to LAs drug at doses as low as 2.5 to 5 μg/mL increased heart rate, and systolic blood pressure acts as a marker for intravascular injection [11].

Ultrasound Gu?dance

US has been observed to decrease the LAST risk by 60%-65% compared to peripheral nerve stimulation alone. US guidance maximizes block success and minimizes complications in nerves, surrounding structures, needle tip, and simultaneous spread of LAs injection allows to be displayed. LAST was not wholly terminated with the use of the US, but a significant decrease was observed in its rate [12,13].

Factors to be considered to reduce the risk of toxicity when applying the block:

  • US-guided application
  • Frequent aspiration
  • Intermittent injection
  • Making a test dose
  • Close follow-up [1,2,12,13].

Awareness, rigorous safety precautions, close monitoring, and proper dose and US guidance to prevent LAST are always required.

Management

Situations that should be done during the development of LAST:

  1. Recognition
  2. Emergency management
  3. Treatment
  4. Close follow-up [1,2,12].

Intravenous (IV) vascular access, oxygen, and standard monitoring should be applied to all patients receiving LAs injections against the possibility of LAST development. Postapplication monitoring should continue for at least 30 minutes. It should be kept in mind that it may develop hours after the completion of the LAST injection. Management of the clinical picture when LAST develops includes general supportive measures and specific therapeutic interventions. When LAST is suspected, LAs injection/infusion should be stopped first, and then cardiopulmonary resuscitation (CPR) should be started [1,2,12,14].

Support?ve Measures

  • Close monitoring
  • Basic supportive measures to ensure airway management, ventilation with 100% oxygen
  • Stop injecting the LAs
  • If necessary, advanced airway device and endotracheal entübation
  • Immediate initiation of CPR and effective CPR (Reduce individual epinephrine boluses to ≤1 μg/kg)
  • Avoiding hypoxia, hypercapnia, acidosis, and also hyperventilation
  • Providing rapid coronary perfusion
  • Reduce the concentration of LAs in the tissue
  • Prompt initiation of IV lipid solution
  • Avoiding vasopressin, Ca++ channel blockers and β-blockers, and other LAs
  • Amiodarone should be preferred as an antiarrhythmic
  • Lidocaine is contraindicated in these situations
  • If CPR is insufficient, consider cardiopulmonary bypass
  • In case of seizure, to ensure airway management, ventilation with 100% oxygen
  • Benzodiazepines should be the first choice drug for seizure control. Propofol (1 mg/kg IV) can control seizures when needed in uncontrolled seizures. However, high doses should be avoided in hemodynamically unstable and elderly patients
  • Seizures should be controlled, and hypoxemia, hypercarbia, and acidosis should be avoided as much as possible
  • If seizures cannot be controlled with benzodiazepines and propofol, neuromuscular blockers can be considered
  • If there is a CVS feature after LAST, patients should be followed up for at least 6 hours, and if there is a CNS picture, at least 2 hours, even if the improvement is achieved
  • If necessary, consider staying in intensive care ünit [12,14].

Intravenous L?p?ds

Intravenous lipid therapy is an essential vital component in LAST therapy. In treating LAST, an intravenous dose of 20% lipid emulsion should be administered initially as a bolus and then continued with infusion, as shown in Table 4. If hemodynamic stability is not achieved, the doses should be doubled. After obtaining hemodynamic stability, lipid infusion should be continued for approximately 10 minutes. The maximum recommended initial lipid dose should be 12 mL/kg [12,14,16].

The mechanism of action of IV lipid administration in treating LAST is explained in three ways:

  1. Helps to redistribute LAs with the “scavenging effect,” where the lipids act as a shuttle
  2. It provides an improvement in cardiac output and blood pressure with a direct effect
  3. The cardioprotective effect reduces ischemic reperfusion injury and improves cardiac function [12,14-17]. Although there are few side effects related to lipid therapy, they have been reported in the literature and presented in Table 5 [16,17].
CONCLUSION

LAST is a significant adverse event in life-threatening anesthesia practice. LAs exert different cellular effects in the CNS and CVS; therefore, the underlying mechanisms of LAST are multifactorial. Awareness, rigorous safety precautions, close monitoring, and proper dose and US guidance to prevent LAST are always required. Critical points in LAST treatment are early lipid emulsion administration, rapid seizure management, and airwayrespiratory and CVS-encouraging drug therapy. In preventing and treating LAST, knowing the underlying mechanisms, risk factors, pharmacokinetics, and pharmacodynamics of LAs drugs are vital in clinical practice for the practicing physician. Anesthesiologists can lead the education and training of those who practice LAs in the hospital setting in preventing and managing LAST.

REFERENCES
  1. El-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: current Perspectives. Local Reg Anesth. 2018; 11: 35-44.
  2. Dillane D, Finucane BT. Local anesthetic systemic toxicity. Can J Anesth. 2010; 57: 368-380.
  3. El-Boghdadly K, Pawa A. The erector spine plane block: plane and simple. Anaesthesia. 2017; 72: 434-438.
  4. Forero M, Adhikary SD, Lopez H, Tsui C, Chin KJ. The Erector Spinae Plane Block. Reg Anesth Pain Med. 2016; 41: 621-627.
  5. Ilfeld BM. Continuous peripheral nerve blocks: a review of the published evidence. Anesth Analg. 2011; 113: 904-925.
  6. Pawa A, Wight J, Onwochei DN, Vargulescu R, Reed I, Chrisman L, et al. Combined thoracic paravertebral and pectoral nerve blocks for breast surgery under sedation: a prospective observational case series. Anaesthesia. 2018;73: 438-443.
  7. Barrington MJ, Weinberg GL, Neal JM. A call to all readers: educating all surgeons on preventing and treatment of local anaesthetic systemic toxicity. ANZ J Surg. 2016; 86: 636-637.
  8. Butterworth JF, Strichartz GR. Molecular mechanisms of local anesthesia a review. Anesthesiology. 1990; 72: 711-734.
  9. Becker DE, Reed KL. Local anesthetics: a review of pharmacological considerations. Anesth Prog. 2012; 59: 90-102.
  10. Di Gregorio G, Neal JM, Rosenquist RW, Weinberg GLM. Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009. Reg Anesth Pain Med. 2010; 35: 181-187.
  11. Gitman M, Barrington MJ. Local anesthetic systemic toxicity: a review of recent case reports and registries. Reg Anesth Pain Med. 2018; 43: 124-130.
  12. Neal JM, Barrington MJ, Fettiplace MR, Gitman M, Memtsoudis SG, Mörwald EE, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: executive summary 2017. Reg Anesth Pain Med. 2018; 43: 113-123.
  13. Bainbridge D, McConnell B, Royse C. A review of diagnostic accuracy and clinical impact from the focused use of perioperative ultrasonography. Can J Anaesth. 2018; 65: 371-380.
  14. Wolfe JW, Butterworth JF. Local anesthetic systemic toxicity: update on mechanisms and treatment. Curr Opin Anesthesiol. 2011; 24: 561.
  15. Fettiplace MR, Weinberg G. The mechanisms underlying lipid resuscitation therapy. Reg Anesth Amp Pain Med. 2018; 43: 138.
  16. Weinberg GL. Lipid infusion therapy: translation to clinical practice. Anesth Analg. 2008; 106: 1340-1342. 17. FettiplaceMR, Ripper R, Lis K, Lin B, Lang J, Zider B, et al. Rapid cardiotonic effects of lipid emulsion infusion. Crit Care Med. 2013; 41: e156-162.
Received : 19 Apr 2023
Accepted : 16 Apr 2023
Published : 19 Apr 2023
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X